6876 Stock Overview
Engages in the research and development of drugs for cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
LAUNXP Biomedical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$19.05 |
| 52 Week High | NT$30.35 |
| 52 Week Low | NT$14.70 |
| Beta | 0 |
| 1 Month Change | 3.53% |
| 3 Month Change | -4.51% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -14.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6876 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 1.1% | 2.2% | 0.3% |
| 1Y | n/a | -1.2% | 27.4% |
Return vs Industry: Insufficient data to determine how 6876 performed against the TW Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 6876 performed against the TW Market.
Price Volatility
| 6876 volatility | |
|---|---|
| 6876 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6876's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6876's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | www.launxp.com |
LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.
LAUNXP Biomedical Co., Ltd Fundamentals Summary
| 6876 fundamental statistics | |
|---|---|
| Market cap | NT$613.20m |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6876 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6876 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6876 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 18:18 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LAUNXP Biomedical Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|